Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-10,952
Closed -$1.33M 1046
2022
Q2
$1.33M Hold
10,952
0.01% 930
2022
Q1
$1.56M Hold
10,952
0.01% 899
2021
Q4
$1.93M Sell
10,952
-1,171
-10% -$196K 0.01% 869
2021
Q3
$1.87M Buy
12,123
+2,417
+25% +$351K 0.01% 760
2021
Q2
$1.31M Sell
9,706
-9,234
-49% -$1.24M 0.01% 791
2021
Q1
$2.5M Buy
18,940
+153
+0.8% +$20.1K 0.01% 672
2020
Q4
$2.22M Hold
18,787
0.01% 666
2020
Q3
$1.98M Hold
18,787
0.01% 783
2020
Q2
$2.01M Sell
18,787
-10,259
-35% -$953K 0.01% 762
2020
Q1
$2.32M Hold
29,046
0.02% 701
2019
Q4
$2.57M Hold
29,046
0.02% 613
2019
Q3
$2.37M Hold
29,046
0.02% 608
2019
Q2
$2.74M Buy
+29,046
New +$2.48M 0.02% 599

Other funds holding NOVT

Aviva's NOVT Position: Q3 2022 in Review

Aviva sold out of Novanta (NOVT) in Q3 2022, closing a stake of 10,952 shares — an estimated $1.33M sold.

Aviva first reported a position in NOVT in Q2 2019 and held it in 13 quarters. The position peaked at $2.74M in Q2 2019. 253 funds tracked by Wall St. Rank hold NOVT as of Q3 2022.

  • Aviva reported no remaining Novanta position as of Q3 2022 after selling out during the quarter.
  • Aviva sold 10,952 Novanta shares in Q3 2022, an estimated $1.33M.
  • Aviva first reported a position in Novanta in Q2 2019 and held it in 13 quarters.
  • Aviva's Novanta position peaked at $2.74M in Q2 2019.
  • 253 funds tracked by Wall St. Rank held Novanta as of Q3 2022.

Based on Aviva's 13F filing for Q3 2022, filed 14 Nov 2022.